chufangao/CTO huggingface dataset:
Clinical trial NCT04610801: Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2
Official title: A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Spray vs. Placebo for Acute COVID-19 Infection
Sponsor: Larkin Community Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Study Period Ended/ Not Completed
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-12-08
Primary completion date: 2022-06-08
Completion date: 2022-08-08
Plan to share individual participant data: NO
Clinical trial NCT03318861: Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
Official title: A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The study was terminated due to lack of efficacy
Enrollment: 17.0 (ACTUAL)
Number of arms: 5.0
Start date: 2017-10-20
Primary completion date: 2018-12-17
Completion date: 2022-09-16
Baseline population: The Full Analysis Set included all participants who were enrolled in the study.
Plan to share individual participant data: NO
Clinical trial NCT04244084: Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection
Official title: Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of MMH-407 in the Treatment of Acute Respiratory Viral Infection
Sponsor: Materia Medica Holding (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 240.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-08
Primary completion date: 2020-04-09
Completion date: 2020-04-09
Clinical trial NCT03541174: A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
Official title: Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)
Acronym: PRECISION
Sponsor: Idorsia Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 730.0 (ACTUAL)
Number of arms: 6.0
Start date: 2018-06-18
Primary completion date: 2021-05-14
Completion date: 2022-04-25
Plan to share individual participant data: NO
Clinical trial NCT04606394: Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
Official title: Peak Inspiratory Flow (PIF) and Dry Powder Inhaler (DPI) Performance in Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: Pulmonary Research Institute of Southeast Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-02
Primary completion date: 2021-12-15
Completion date: 2021-12-15
Limitations and caveats: No primary information was available to derive power calculations to estimate the number of subjects needed to test the study hypothesis
Plan to share individual participant data: NO
Clinical trial NCT02991482: PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
Official title: A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma
Acronym: PROMISE-meso
Sponsor: ETOP IBCSG Partners Foundation (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 144.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-12
Primary completion date: 2019-02-20
Completion date: 2021-11-30
Plan to share individual participant data: NO
Clinical trial NCT04340193: A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer
Official title: A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)
Acronym: CheckMate 74W
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Slow accrual
Enrollment: 26.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-09-15
Primary completion date: 2023-12-12
Completion date: 2023-12-12
Clinical trial NCT03330106: A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
Official title: A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 68.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-11-15
Primary completion date: 2019-01-07
Completion date: 2021-06-21
Baseline population: Randomized Population included all participants who had a randomization date and had been randomized to a treatment sequence.
Plan to share individual participant data: YES
IPD sharing description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
IPD access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Clinical trial NCT01453088: Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older
Official title: (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
Sponsor: Hackensack Meridian Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of Accrual
Enrollment: 63.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-06-24
Primary completion date: 2022-05-01
Completion date: 2022-05-01
Clinical trial NCT05313386: Study of BXCL501 In Agitation Associated With Delirium in ICU Patients
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled, Ascending Starting Dose Finding, Safety, and Efficacy Study of BXCL501 in Agitation Associated With Delirium in ICU Patients.
Sponsor: BioXcel Therapeutics Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: The study stopped early, before enrolling its first participant
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-02-23
Primary completion date: 2022-02-21
Completion date: 2022-02-21
Clinical trial NCT01870505: BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Official title: A Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 4.0
Start date: 2013-05-31
Primary completion date: 2022-02-28
Completion date: 2022-02-28
Clinical trial NCT05061654: CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients
Official title: CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients; a Single-arm, Single-center, Open-label Clinical Trial (CEF-10 Study)
Acronym: CEF-10
Sponsor: Hamad Medical Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Administrative constraints
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-08-31
Primary completion date: 2024-01-31
Completion date: 2024-06-30
Plan to share individual participant data: NO
Clinical trial NCT04041674: Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants
Official title: A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants *Imatinib Mesylate Per Oral as a Clinical Therapeutic for TB
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Protocol undergoing additional revisions.
Enrollment: 0.0 (ACTUAL)
Number of arms: 5.0
Start date: 2022-03-01
Primary completion date: 2022-09-30
Completion date: 2023-05-31
Plan to share individual participant data: NO
Clinical trial NCT03034538: An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease
Official title: An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease
Sponsor: The Cooper Health System (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: SUSPENDED 
Why stopped: Site staffing
Enrollment: 20.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2016-04-08
Primary completion date: 2022-12-01
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT04854512: Investigational Study of Delayed Release Metformin
Official title: Randomized, Multicenter, Double-blind, Parallel-Group, Placebo & Comparator-Controlled Study to Compare the Glycemic Effects, Safety & Tolerability of Metformin Delayed-Release Tablets in Patients With Type 2 Diabetes Mellitus
Acronym: DREAM-T2D
Sponsor: Anji Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Strategic company decision - not related to a safety concern
Enrollment: 675.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2021-05-18
Primary completion date: 2023-12-01
Completion date: 2024-06-30
Plan to share individual participant data: NO
Clinical trial NCT04486326: Crofelemer for Functional Diarrhea
Official title: Crofelemer for Functional Diarrhea
Sponsor: Beth Israel Deaconess Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: low enrollment
Enrollment: 17.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-20
Primary completion date: 2022-09-23
Completion date: 2022-09-23
Plan to share individual participant data: NO
Clinical trial NCT04115020: Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis
Official title: Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis
Sponsor: Brigham and Women's Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: A pilot study was negative.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-31
Primary completion date: 2020-01-07
Completion date: 2020-01-07
Plan to share individual participant data: YES
IPD sharing description: A de-identified, anonymized dataset containing all the primary study data will be created and shared consistent with institutional policies. This dataset will be included as a supplementary file attached to the published manuscript, which in turn will be available through PubMed Central. In the event that the study has not been published, the dataset will be made available by other means within 3 years of study completion. The publicly available dataset will not include any identifiers, e.g. age will be included but not birthdate
IPD time frame: Protocol will be uploaded when results are reported.
Clinical trial NCT04360135: Preemptive Acetaminophen for Postoperative Pain Control Following Minimally Invasive Hysterectomy
Official title: Preemptive Acetaminophen for Postoperative Pain Control Following Minimally Invasive Hysterectomy: a Randomized Control Trial
Sponsor: Montefiore Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: The study was closed on 3/8/2021 as per final progress report issued by the IRB on 3/12/2021. No subjects were enrolled in the study following approval. Status changed to Withdrawn (No Participants Enrolled) accordingly.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-06
Primary completion date: 2021-03-08
Completion date: 2021-03-08
Plan to share individual participant data: NO
Clinical trial NCT03240068: Angiotensin-(1-7) in Peripheral Arterial Disease
Official title: Protective Effects of Angiotensin-(1-7) in Peripheral Arterial Disease
Sponsor: Milton S. Hershey Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Study funding ended prior to completion.
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-09-01
Primary completion date: 2020-03-09
Completion date: 2020-03-09
Plan to share individual participant data: NO
Clinical trial NCT03143985: Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma
Official title: A Phase 1b Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM)
Sponsor: Case Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 18.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-21
Primary completion date: 2022-02-27
Completion date: 2022-09-01
Clinical trial NCT04336748: HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers
Official title: Low-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled Trial
Sponsor: Medical University of Vienna (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Not feasible
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-30
Primary completion date: 2020-07-31
Completion date: 2020-08-31
Clinical trial NCT04533399: A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults
Official title: A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1™ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV
Sponsor: Novavax (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 4422.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-08-17
Primary completion date: 2021-12-07
Completion date: 2022-01-19
Plan to share individual participant data: NO
Clinical trial NCT03920059: Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis
Official title: A Randomized Open-label Study of Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis
Sponsor: Chulalongkorn University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Slow recruitment rate
Enrollment: 2.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-20
Primary completion date: 2020-01-30
Completion date: 2020-01-30
Clinical trial NCT01966471: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
Official title: A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1846.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-01-31
Primary completion date: 2019-11-27
Completion date: 2021-06-04
Baseline population: Baseline Measures are based on the Intent-to-Treat (ITT) population.
Clinical trial NCT03907072: Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
Official title: A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)
Acronym: DYSTANCE 51
Sponsor: Wave Life Sciences Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 6.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-04
Primary completion date: 2019-12-16
Completion date: 2020-01-09
Clinical trial NCT04371640: Sirolimus in COVID-19 Phase 1
Official title: A Randomized, Double-Blinded, Placebo-Controlled Trial Evaluating the Virological Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Sirolimus Adjuvant Therapy in Patients With Coronavirus Disease (COVID-19)
Acronym: SirCO-1
Sponsor: Thomas Jefferson University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Study population not regularly admitted to hospital and approaches have shifted away from repurposing old drugs.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-06
Primary completion date: 2021-07-30
Completion date: 2021-07-30
Plan to share individual participant data: NO
Clinical trial NCT05084560: Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
Official title: Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
Acronym: AWOL
Sponsor: Liverpool School of Tropical Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Safety issues
Enrollment: 30.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-10
Primary completion date: 2023-05-22
Completion date: 2023-05-22
Plan to share individual participant data: NO
IPD sharing description: Commercial sensitivity
Clinical trial NCT04707625: Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment
Official title: Correlation of Vascular Endothelial Growth Factor Levels in Anterior Chamber Fluid to Disease State in Patients With Retinal Vein Occlusion Receiving Standard of Care Treatment
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: IRB stopped study due to safety concerns. No further data collection and what has been collected is not appropriate for analysis.
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-10-06
Primary completion date: 2023-12-18
Completion date: 2023-12-18
Plan to share individual participant data: NO
IPD sharing description: There is no plan to share IPD at this time.
Clinical trial NCT04614051: Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC)
Official title: An Open Label, Single-center, Phase 1 Study to Evaluate the Safety of Cancer Immunotherapy With Autologous Dendritic Cells in Patients With Advanced or Recurrent Epithelial Ovarian Cancer
Sponsor: Pharmicell Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Difficult recruitment
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-30
Primary completion date: 2022-05-10
Completion date: 2022-05-10
Clinical trial NCT04173780: Topical 0.01% Atropine for the Control of Fast Progressing Myopia
Official title: Topical 0.01% Atropine for the Control of Fast Progressing Myopia
Acronym: Myopie-STOP
Sponsor: University Hospital, Strasbourg, France (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: recruitment difficulties
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-12
Primary completion date: 2024-05-15
Completion date: 2024-06-03
Plan to share individual participant data: NO
Clinical trial NCT03687333: Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment
Official title: A Single Arm, Prospective, Open-label, Multi-center Study to Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment
Acronym: APOLLO-IOPD
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-12-04
Primary completion date: 2020-12-30
Completion date: 2020-12-30
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03824704: A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Official title: A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Sponsor: pharmaand GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor made a business decision to discontinue the study due to low accrual.
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-23
Primary completion date: 2020-08-24
Completion date: 2020-08-24
Limitations and caveats: The Sponsor made a business decision to discontinue the study due to low accrual.